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Abstract 
Background 
Findings from observational and experimental studies suggest that maternal inflammation during pregnancy 
is associated with autism spectrum disorder (ASD). We report the first study in humans to examine this association 
in a large prospective birth cohort.  
Methods 
We studied 788 mother-child pairs from the Seychelles Child Development Study Nutrition Cohort 2. 
Thirteen inflammatory markers were measured in mothers’ serum at 28 weeks’ gestation, along with the sum of T-
helper 1 (Th1) and 2 (Th2) cytokines. The Social Communication Questionnaire (SCQ) and Social Responsiveness 
Scale (SRS) were administered at age 7 years to obtain information on ASD phenotype. We evaluated associations 
between maternal inflammatory markers and ASD phenotype using multivariable linear regression.  
Results 
For the SCQ, increased MCP-1 (a chemokine that is upregulated in response to pro-
inflammatory cytokines) was associated with fewer ASD symptoms (B = -0.40; 95% CI = -0.72, -0.09). Increased 
IL-4 (a cytokine that is typically associated with an enhanced anti-inflammatory response) was associated with more 
ASD symptoms (B = 2.10; 95% CI = 0.78, 3.43). For the SRS, higher concentrations of the anti-inflammatory 
cytokine IL-10 were associated with fewer ASD symptoms (B = -0.18; 95% CI = -0.35, -0.01), but only after 
removal of outliers. No associations were observed for other markers.  
Conclusions 
These findings suggest that a shift in the maternal immune balance during pregnancy may be associated 
with ASD symptomatology. While the use of well-established measures that capture ASD phenotypic variability is a 
strength of the study, measurement of peripheral immune markers only once during gestation is a limitation. Our 
results should be confirmed using maternal immune markers measured throughout gestation.    
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Introduction 
 
Autism spectrum disorder (ASD) is characterized by persistent difficulties of varying severity in social 
interaction and communication, and restricted or repetitive behaviors and interests [1]. The reported prevalence has 
increased in the past several decades, with an estimated one in every 59 children having an ASD diagnosis by eight 
years of age in the United States [2]. The precise etiology of ASD remains unknown [3]. 
 Maternal inflammation during prenatal development is hypothesized to be associated with the pathogenesis 
and severity of ASD [4]. The immune system works during pregnancy to ensure that the maternal fetal environment 
is protected from external pathogens while also preventing inflammatory dysregulation that could lead to 
miscarriage [5]. The balance of pro- versus anti-inflammatory cells shifts throughout pregnancy to support this 
immune function. In the first trimester, T-helper 1(Th1)-type cytokines are released as part of cell-mediated 
inflammatory reactions in response to the fetus as a foreign body [6–9]. During the second and early-third trimesters, 
there is a subsequent downregulation of Th1-type cells in favor of T-helper 2 (Th2)-type immunity in order to 
prevent rejection of the fetus [6–9]. In the mid- to late-third trimester, there is an upregulation of Th1 cells and 
downregulation of Th2 cells to promote contractions of the uterus and subsequent delivery of the baby and placenta 
[10].  
Infections or immune dysregulation may harm fetal neural and immune system development if present 
during critical or sensitive periods [11–13], thereby potentially contributing to the likelihood of ASD [14]. A study 
of all children born in Denmark from 1980 to 2005 found that hospital admissions due to maternal viral infection in 
the first trimester and maternal bacterial infection in the second trimester were associated with a significantly 
increased risk of an ASD diagnosis in their children [15]. Another study using data from a cohort of infants born in 
California found no overall association between any diagnosis of maternal infection during pregnancy and ASD, but 
children of women diagnosed with an infection during a hospital admission were more likely to have a diagnosis of 
ASD [16]. Prenatal exposure to multiple infections was also associated with ASD in that study [16]. A retrospective-
cohort study using data from the Western Australian Autism Biological Registry found that maternal immune 
activation history (i.e., a history of allergies and asthma) during pregnancy was associated with greater severity of 
childhood ASD symptoms as measured by the Social Responsiveness Scale [17]. 
Animal models have demonstrated an association between activation of the maternal immune system 
during pregnancy and possibility of ASD-type behaviors in offspring [18]. Maternal administration of poly(I:C) in 
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pregnant mice at gestational day 12.5 resulted in an upregulation of IL-6 that was associated with increased anxiety 
and social interaction deficits in offspring [19]. Although the role of specific cytokines was not assessed, pregnant 
mice injected with poly(I:C) in another study had offspring that exhibited high levels of repetitive behaviors and 
deficits in reciprocal social interaction [20]. 
Of relevance to the current study, several epidemiologic case-control studies have reported associations 
between childhood ASD phenotype and specific cytokines and chemokines measured in maternal sera during 
pregnancy. These studies reported that higher levels of early-pregnancy C-reactive protein (CRP) were associated 
with increased ASD risk [21] and, conversely, that higher levels of mid-pregnancy CRP were associated with 
decreased ASD risk [22]. Goines and colleagues [23] found that, among more than one dozen markers assessed, 
increased concentrations of interferon (IFN)-γ, interleukin (IL)-4 , and IL-5 in maternal sera at 15 to 19 weeks 
gestation were associated with an increased risk of ASD diagnosis in their children. However, their sample size was 
limited to 84 children with ASD, 49 children with developmental delay but not ASD, and 159 children without ASD 
or developmental problems. Authors from the same research group [24] conducted a similar but larger study and 
reported decreased levels of IFN-γ, IL-8, and monocyte chemoattractant protein (MCP)-1 in mid-gestational sera of 
mothers whose children developed ASD without intellectual disability as compared to controls without ASD or 
developmental problems [24]. Using dried neonatal blood spots [25–29] or mid-gestational amniotic fluid samples 
[30, 31], other case-control studies suggest that the following are associated with an increased probability of ASD: 
increased MCP-1 [29, 31], increased IL-1β [28], either increased [28, 30] or decreased [25] IL-4, increased IL-10 
[30], increased tumor necrosis factor (TNF)-α [30], and decreased IFN-γ, IL-2, and IL-6 [25].  
No studies have assessed the association between maternal inflammatory markers and ASD prospectively, 
and there are few replicated findings. In addition, studies of more subtle measures capturing variability in ASD 
phenotype have not been carried out. The current study adds to this limited literature by evaluating data from the 
Seychelles Child Development Study (SCDS) Nutrition Cohort 2 (NC2). This is a large, well-characterized 
prospective birth cohort from the Republic of Seychelles with the primary goal of evaluating whether prenatal 
exposure to methylmercury and nutrients from high fish consumption during pregnancy influences child 
development [32]. As part of this study we measured 13 prenatal markers of inflammation and obtained data from 
parent surveys about their child’s ASD symptomatology at 7 years of age. We used two widely-accepted ASD 
screening instruments to characterize the presence and severity of ASD-related symptoms [33, 34], as opposed to 
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relying on categorical clinical diagnoses of ASD as in previous studies. Based on existing literature, we 
hypothesized that increased concentrations of IFN-γ [24, 25], MCP-1 [24], and CRP [22] in maternal serum at 28 
weeks gestation would be associated with fewer ASD symptoms at 7 years of age. Conversely, we hypothesized that 
increased concentrations of IL-4, IL-10, and TNF-α would be associated with more ASD symptoms [30].  
Methods and Materials 
Study Population 
The SCDS NC2 cohort has been described in detail elsewhere [32]. In short, 1518 pregnant women were 
recruited from 2008 to 2011 during an early antenatal visit (from 14 weeks’ gestation). Inclusion criteria for NC2 
included being native Seychellois, being 16 years of age, having a singleton pregnancy (if known at recruitment), 
and having no obvious health concerns [32]. Children were tested for various developmental outcomes at about 20 
months and 7 years of age. Developmental testing for this cohort is ongoing, but we examined a subset of 
participants (n = 788) with currently available data on ASD phenotyping measures at 7 years, inflammatory markers 
in maternal sera at 28 weeks’ gestation, and relevant covariates (see “Covariates”).  
As in previous analyses [32], exclusions were made for factors known to significantly affect 
neurodevelopment, including birthweight <1500 g (n = 4), maternal pre- or perinatal complications (n = 1), head 
trauma with loss of consciousness > 1 minute (n = 2), and recurrent afebrile seizures (n = 13). We also excluded 
twins (n = 20) because of the potential for differences in the prenatal environment between twins and singletons.  
After exclusions, the final overall sample size was 748, with sample sizes ranging from 691 to 702 per analysis due 
to missing data in inflammatory markers or covariates, and ranging from 687 to 697 after outlier removal (see 
“Statistical Analyses”). 
The study was reviewed and approved by the Seychelles Ethics Board and the Research Subjects Review 
Board at the University of Rochester. 
ASD Phenotype Assessment 
The Social Communication Questionnaire (SCQ) [34] and Social Responsiveness Scale (SRS) [33] were 
administered when cohort children were around 7 years of age (M = 7.19, SD = 0.10, range = 6.25 – 7.80 years) to 
obtain information on ASD phenotype. The SCQ is a 40-item parent rating scale of ASD symptomatology with 
responses in yes-or-no format. Questions assess lifetime presence of symptoms (items 2 – 19), and symptoms 
present between the child’s fourth and fifth birthdays (items 20 – 40). The SCQ yields a total score ranging from 0 – 
 6
 
39 (the first item is a screener for the use of spoken language and is not included in the total score), with higher 
scores indicating more ASD symptoms. The average SCQ total score for the current sample was 8.50 (SD = 4.17, 
range: 0 – 22). The screening cut-off for potential ASD is a total score  15 [34, 35].  
The SRS is a 65-item parent rating scale of ASD symptomatology present over the 6 months prior to 
administration. Items are rated on a Likert-type scale from 0 (“not true”) to 3 (“almost always true”). The SRS yields 
a total score ranging from 0 – 195, with higher scores indicating more ASD-related symptoms. The average SRS 
total score for the current sample was 48.27 (SD = 19.17, range: 6 – 137). A total score  70 for males and  65 for 
females is recommended as the cut-off for possible ASD when screening unselected general-population groups [33].  
Inflammatory Markers 
Non-fasting blood samples were collected at a mean of 28 weeks of gestation (range: 20.14 – 33.29 weeks, 
SD = 1.03). Samples were collected by antecubital venipuncture into evacuated serum tubes. They were placed on 
ice and allowed to sit for 30 minutes before being centrifuged at 2500 rpm for 15 minutes. Aliquots were shipped to 
Ulster at -80°C and stored until analysis. Analysis of serum inflammatory markers took place approximately five 
years after sample collection and were analyzed at Ulster University using Meso Scale Discovery (MSD) multiplex 
assay (Meso Scale Diagnostics, LLC). These assays yield greater sensitivity, larger dynamic range, and require less 
sample volume than traditional methods for immunoassays [36].  
The cytokines that were measured for cell-mediated pro-inflammatory reactions included IL-1β, IL-2, IFN-
γ, and TNF-α. The cytokines associated with anti-inflammatory β-cell activation and antibody production included 
IL-4, IL-5, and IL-10. Measured cytokines were also used to estimate Th1:Th2, defined as Th1 (sum of IL-1β, IL-2, 
IFN-γ, and TNF-α) divided by Th2 (sum of IL-4, IL-5, IL-10, and IL-6). This ratio provides an approximation of the 
balance of cytotoxic (Th1) versus humoral immune (Th2) responses. IL-6, which has both pro- and anti-
inflammatory roles [37], was also measured. Additional markers included CRP; the chemokines MCP-1 and thymus 
and activation regulated chemokine (TARC); and the angiogenesis markers soluble fms-like tyrosine kinase (sFlt)-1 
and vascular endothelial growth factor (VEGF)-D. Individual biomarkers were analyzed as continuous variables 
measured in pg/mL, except CRP which was measured in mg/L.  
Values below the limit of detection for each marker were imputed as LLOD/√2, as recommended by others 
[38]. Two markers had a substantial amount (> 20%) of undetectable values: IL-2 and IL-4. Due to their relatively 
low concentrations, excluding IL-2 and IL-4 from the Th1, Th2 and Th1:Th2 variables had little impact on 
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associations studied with developmental outcomes at 20 months in this cohort [Irwin et al. submitted], and thus these 
markers were included both as individual variables and within the Th1, Th2, and Th1:Th2 variables in the current 
analyses.  
Covariates 
 Our regression models adjusted for demographic covariates based on their known or suspected relationship 
with ASD phenotype as identified in a recent meta-analysis of prenatal, perinatal, and postnatal factors associated 
with ASD [39]: maternal age, child sex, Hollingshead socioeconomic status (SES), and parity (1 child versus 2+ 
children). Information on paternal age was not available. Both maternal age and Hollingshead SES (possible range 
8-66, with higher scores indicating higher SES) were included as continuous variables.  
Statistical Analyses 
First, we calculated measures of central tendency and variance to describe demographics, ASD phenotype, 
and inflammatory markers in mothers and children. To correct for significant skewness in the inflammatory marker 
variables, each was loge-transformed after adding a constant of one to prevent taking the natural logarithm of zero. 
In addition, the SRS total score was square-root transformed to correct for significant skewness. Transformed 
variables were used in all analyses, with the exception of the descriptive analyses presented in Table 1. 
Primary analyses consisted of 16 separate multivariable regression models, separately for SCQ and SRS. 
We examined each of the 13 individual biomarkers (IL-1β, IL-2, IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-10, MCP-1, 
TARC, sFlt-1, VEGF-D, CRP) as well as total Th1, Th2, and Th1:Th2 as continuous predictors. In secondary 
analyses we evaluated the independent association for each individual marker after accounting for other markers. 
We also performed regression with all 13 individual markers in one model, and total Th1 and Th2 together in 
another model. Results of the secondary analyses were identical in interpretation to the results of the primary 
analyses, thus only results of the primary analyses are presented below.  
Prior to running the analysis, each model was examined for the presence of influential points (Cook’s 
distances larger than 0.50) or statistical outliers (standardized residuals in excess of 3), as has been done previously 
[40]. There were no influential points, but 4-6 statistical outliers were identified depending on the model. 
Observations that were statistical outliers had significantly higher mean SRS (M= 98.17, SD= 30.31) and SCQ (M= 
17.00, SD= 3.88) scores compared to the rest of the sample. Each regression model was then also run without its 
respective outliers included.   
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For each analysis, a p value less than 0.05 was considered statistically significant. All statistical analyses 
were conducted using SAS (v9.4, SAS Institute Inc., Cary, NC, USA).  
Results 
 Summary statistics for the participants and variables included in the study are presented in Tables 1 and 2. 
Figures 1 and 2 include the results of the analyses investigating whether each individual inflammatory marker 
variable, as well as Th1, Th2, and Th1:Th2 is associated with the SCQ total score (Figure 1) and the SRS total score 
(Figure 2), each in separate models.  
For the SCQ, higher concentrations of MCP-1, a chemokine upregulated in response to pro-inflammatory 
cytokines, were associated with fewer ASD symptoms, as hypothesized. Also as hypothesized, higher concentrations 
of IL-4, a cytokine typically associated with an enhanced anti-inflammatory response, were associated with more 
ASD symptoms. No other inflammatory marker variables (IL-1β, IL-2, IFN-γ, TNF-α, IL-5, IL-10, IL-6, TARC, 
sFlt-1, VEGF-D, CRP, Th1, Th2, Th:Th2) were significantly associated with SRS or SCQ total scores. After 
removal of outliers, model results were similar to those using the full sample, although the association between 
higher concentrations of IL-10 and fewer ASD symptoms measured by the SRS became statistically significant (B = 
-0.18; 95% CI = -0.35, -0.01).   
Across all models, sex and Hollingshead SES were associated with SRS and SCQ total scores; being 
female and mothers having higher SES were associated with fewer ASD symptoms. Mothers’ age at enrollment and 
parity were not associated with SRS or SCQ scores in any models. 
Discussion 
 The current study evaluated whether circulating maternal inflammatory markers at 28 weeks’ gestation are 
associated with child ASD phenotype at 7 years. We hypothesized that increased concentrations of CRP, IFN-γ, and 
MCP-1 would be associated with reduced ASD symptomatology and increased IL-4, IL-10, and TNF-α 
concentrations would be associated with elevated ASD symptomatology. These hypotheses were confirmed for 
MCP-1 and IL-4, but not for CRP, IFN-γ, IL-10, and TNF-α. Contrary to our hypothesis, higher concentrations of 
IL-10 were associated with fewer ASD symptoms, although this association was only statistically significant after 
removal of outliers. 
 MCP-1 is a chemokine that plays a key role in the polarization of cells toward a Th2 phenotype through its 
recruitment of activated T cells, monocytes, and basophils to sites of inflammation or tissue injury [41]. A study 
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using mice found that activation of the maternal innate immune system via poly(I:C) triggers an upregulation of 
MCP-1 that is also evident in the fetal brain, which could theoretically impair the brain’s ability to form neuronal 
connections [42]. Nevertheless, other research has found that MCP-1 supports a neuroprotective role by causing 
proliferation of microglia that protect the central nervous system from pathogens [43].  MCP-1 was associated with 
reduced ASD symptomatology, consistent with prior research on children with ASD without intellectual disability 
[24]. This finding suggests that the association may also extend to children unselected for ASD diagnostic status 
who exhibit the full range of phenotypic variability across the autism spectrum. 
A Th2-dominant profile in normal pregnancy is thought to reduce the maternal response to fetal antigens, in 
particular when IL-4 and IL-10 concentrations are especially elevated [9]. The primary function of IL-4 in 
pregnancy is the activation of B-cells and suppression of Th1 cells, and the primary function of IL-10 in pregnancy 
is to inhibit macrophage cytokine production [44]. IL-4 is associated with an enhanced Th2 response which in a 
normal situation is associated with antibody production and the clearance of antigens. However, if it is maintained or 
occurs where the antigen is a self-antigen, it could serve to prolong inflammation [45]. In our sample, increased IL-4 
concentrations were associated with elevated ASD symptomatology, whereas increased IL-10 concentrations were 
associated with reduced ASD symptomatology. This is possibly reflective of an association between immune 
dysregulation and ASD symptomatology. Our initial hypotheses that increased IL-4 and IL-10 would be associated 
with elevated ASD symptomatology were based on findings that suggested a higher probability of ASD diagnosis 
with increased IL-10 and IL-4 in amniotic fluid [30]. However, a study of normative cytokine concentrations in 
pregnancy found that mid-gestational concentrations of IL-10 were detectable in only 34% of amniotic fluid 
samples, whereas they were detectable in 100% of maternal serum samples [44].  Consequently, findings using IL-
10 concentrations in amniotic fluid may not be comparable to those using maternal sera. Concentrations of IL-4, 
however, were detectable in 100% of both maternal serum and amniotic fluid samples in that study [44].  
This study has important strengths, in particular its use of a large prospective birth cohort of children, the 
relatively large panel of inflammatory markers, and the use of continuous measures of ASD symptomatology as 
opposed to clinical ASD diagnostic status. We used two widely-accepted ASD screening instruments to characterize 
the presence and severity of ASD-related symptoms [33, 34], examining ASD features along a continuum in order to 
capture the full range of phenotypic variability [46, 47]. The use of these continuous measures in a prospective birth 
cohort also allowed us to have roughly equivalent numbers of males and females in the sample. Females are less 
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likely than males to receive an ASD diagnosis even when exhibiting equivalent high levels of autistic-like traits 
[48], and are therefore underrepresented in observational studies of ASD or related phenotypes. Finally, we were 
able to confirm known associations for covariates included in our analyses, further increasing the confidence in our 
findings. For example, the significant association with socioeconomic status is in line with recent research 
suggesting that both SRS and SCQ scores are impacted by maternal education and family income [49]. Also, sex 
differences in ASD symptomatology were as expected based on findings from general population groups indicating 
that males tend to have higher scores on both the SRS[33] and SCQ[50] compared to females.  
Our study also has several limitations. Concentrations of inflammatory markers are known to fluctuate 
throughout pregnancy [8, 9]; therefore concentrations at 28 weeks gestation likely vary from concentrations at other 
time points that were not measured in the current study. Furthermore, although we excluded mothers and children 
with certain clinical conditions from the analysis, we lacked information on whether the mothers had particular 
inflammatory or autoimmune conditions, which might impact concentrations of inflammatory markers. In addition, 
measurable levels of inflammatory markers can be affected by the time samples spent in storage (in this study, 
approximately five years), for example due to cytokine degradation [51]. However, all samples in the current study 
underwent the same conditions of freezing, storage, and thawing, and we would not expect the impact of storage on 
inflammatory marker concentrations to vary based on ASD phenotype or other variables in the model.  
In conclusion, our findings in a large prospective cohort suggest that a shift in the maternal immune 
balance during pregnancy may be associated with ASD symptomatology. Our results should be confirmed using 
longitudinal measurements of maternal inflammatory markers throughout gestation.   
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Table and Figure Titles/Legends: 
Table 1: Summary statistics for ASD phenotype at 7 years of age, and model covariates. 
 
Note. ASD: Autism Spectrum Disorder; SRS: Social Responsiveness Scale; SCQ: Social Communication 
Questionnaire; SES: socioeconomic status.  
 
Table 2: Summary statistics for maternal inflammatory markers at 28 weeks gestation. 
 
Note. LOD: limit of detection; IL-1β: Interleukin-1β; IL-2: Interleukin-2; IFN-γ: Interferon-γ; TNF-α: Tumor 
Necrosis Factor- α; Th1: Sum of IL-1β, IL-2, IFN-γ, TNF-α; IL-4: Interleukin-4; IL-5: Interleukin-5; IL-10: 
Interleukin-10; Th2: Sum of IL-4, IL-5, IL-10; IL-6: Interleukin-6; MCP-1: Monocyte Chemoattractant 
Protein-1; TARC: Thymus and Activation Regulated Chemokine; sFlt-1: Soluble Fms-like Tyrosine Kinase-
1; VEGF-D: Vascular Endothelial Growth Factor-D; CRP: C-reactive protein; ASD: Autism Spectrum 
Disorder; SRS: Social Responsiveness Scale; SCQ: Social Communication Questionnaire. Serum 
biomarkers measured in pg/mL, except CRP which was measured in mg/L. Descriptive analyses presented 
are using raw variables prior to transformation. 
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Figure 1: Primary main effects models for continuous maternal gestational inflammatory markers 
at 28 weeks and the Social Communication Questionnaire at 7 years of age. 
 
Note. Primary analyses include individual markers, Th1, and Th2 in separate models. Estimated 
regression coefficients and corresponding 95% confidence intervals are shown, after adjustment 
for the following covariates: maternal age at enrollment, child sex, parity, and Hollingshead 
socioeconomic status. *p < 0.05; **p < 0.01. Th1: Sum of IL-1β, IL-2, IFN- γ, TNF-α; Th2: Sum 
of IL-4, IL-5, IL-10. All inflammatory marker variables were log-transformed, as outlined in 
text. 
 
Figure 2: Primary main effects models for continuous maternal gestational inflammatory markers 
at 28 weeks and the Social Responsiveness Scale at 7 years of age. 
 
Note. Primary analyses include individual markers, Th1, and Th2 in separate models. Estimated  
regression coefficients and corresponding 95% confidence intervals are shown, after adjustment  
for the following covariates: maternal age at enrollment, child sex, parity, and Hollingshead  
socioeconomic status. Th1: Sum of IL-1β, IL-2, IFN- γ, TNF-α; Th2: Sum of IL-4, IL-5, IL-10.  
All inflammatory marker variables were log-transformed, as outlined in text.  
 
  n M (SD) or n (%) Minimum Median Maximum 
ASD Phenotype Measures      
SRS total score 747 48.27 (19.17) 6 47.00 137 
SCQ total score 746 8.50 (4.17) 0 8 22 
Covariates      
Child sex (male or female) 748 400 (53.5%) males    
Mother’s age at enrollment 747 26.61 (6.14) 16.03 25.72 46.56 
Parity (first child vs. 2+ children) 739 372 (50.3%) first child    
Hollingshead SES 742 33.10 (10.60) 12.50 32.00 63.00 
 
 
 
 
  n M (SD) or n (%) Minimum Median Maximum 
Maternal Serum Biomarkers      
Th1      
IL-1β 718 0.26 (0.58) 1.00E-04 0.09 11.91 
IL-2 718 0.24 (0.60) 76.3% ≤ LOD (0.09) 0.62 9.97 
IFN-γ 718 5.43 (20.30) 0.04 2.48 449.91 
TNF-α 718 5.98 (8.54) 0.03 4.46 125.57 
∑ Th1 718 11.90 (22.91) 0.21 7.75 456.99 
Th2      
IL-4 718 0.14 (0.64) 77.0% ≤ LOD (0.02) 0.24 11.83 
IL-5 718 1.40 (2.61) 1.59E-03 0.72 31.96 
IL-10 718 1.21 (1.88) 1.02E-03 0.73 25.72 
∑ Th2 718 2.74 (3.51) 0.05 1.93 32.36 
Other      
Th1:Th2 718 8.32 (14.05) 0.04 4.79 220.00 
IL-6 718 0.83 (1.40) 3.43E-03 0.42 14.65 
MCP-1 718 66.61 (53.22) 0.02 58.41 903.61 
TARC 718 112.20 (186.65) 0.12 80.85 2541.00 
sFlt-1 718 2012.68 (1093.85) 324.63 1772.03 8523.58 
VEGF-D 718 805.46 (403.84) 44.71 725.71 2814.71 
CRP 708 3.31 (2.64) 0 2.50 9.73 
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IL-5 701 0.04 (-0.54, 0.61)
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∑ Th2 701 0.29 (-0.19, 0.77)
Other
Th1:Th2 701 -0.01 (-0.38, 0.36)
IL-6 701 0.46 (-0.22, 1.13)
MCP-1 701 -0.40 (-0.72, -0.09)*
TARC 701 -0.18 (-0.46, 0.10)
sFlt-1 701 0.38 (-0.18, 0.94)
VEGF-D 701 0.57 (-0.01, 1.16)
CRP 691 -0.15 (-0.64, 0.33)
Marker n B (95% CI)
B Estimate
-1.5 -1 -0.5 0 0.5 1 1.5 2 2.5 3 3.5
Th1
IL-1β 701 0.14 (-1.09, 1.37)
IL-2 701 0.13 (-1.00, 1.26)
IFN-γ 701 0.13 (-0.19, 0.46)
TNF-α 701 0.32 (-0.18, 0.82)
∑ Th1 701 0.26 (-0.15, 0.67)
Th2
IL-4 701 2.10 (0.78, 3.43)**
IL-5 701 0.04 (-0.54, 0.61)
IL-10 701 0.27 (-0.29, 0.84)
∑ Th2 701 0.29 (-0.19, 0.77)
Other
Th1:Th2 701 -0.01 (-0.38, 0.36)
IL-6 701 0.46 (-0.22, 1.13)
MCP-1 701 -0.40 (-0.72, -0.09)*
TARC 701 -0.18 (-0.46, 0.10)
sFlt-1 701 0.38 (-0.18, 0.94)
VEGF-D 701 0.57 (-0.01, 1.16)
CRP 691 -0.15 (-0.64, 0.33)
Marker n B (95% CI)
B Estimate
